256229-10-4

Basic information

• Product Name: (2RS)-2-benzyloxy-3-phenylpropanal
• Synonyms: (2RS)-2-benzyloxy-3-phenylpropanal
• CAS NO: 256229-10-4
• Molecular Weight: 240.302
• Mol File: 256229-10-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (2RS)-2-benzyloxy-3-phenylpropanal(CAS DataBase Reference)
• NIST Chemistry Reference: (2RS)-2-benzyloxy-3-phenylpropanal(256229-10-4)
• EPA Substance Registry System: (2RS)-2-benzyloxy-3-phenylpropanal(256229-10-4)

Safety Data

• Hazardous Substances Data: 256229-10-4(Hazardous Substances Data)

Upstream product

• 1450842-95-1 C₁₉H₂₂OS₂ 
• 122-78-1 phenylacetaldehyde 
• 110298-77-6 α-Benzyloxyhydrozimtsaeuremethylester 
• 13674-16-3 methyl 2-hydroxy-3-phenylpropanoate 
• 828-01-3 phenyllactic acid 
• 380892-92-2 (2RS)-2-O-benzyl-1-phenyl-3-buten-2-ol 
• 6052-66-0 1-phenyl-3-buten-2-ol 

Downstream Products

• 98944-52-6 (2R,3S)-3-Benzyloxy-2-hydroxy-butyronitrile 
• 851981-40-3 2-O-benzyl-1-phenyl-7-octen-2,3-diol 
• 102-16-9 benzyl 2-phenylacetate 
• 3085-54-9 N-(4-methylphenyl)formamide 
• 13959-92-7 benzyl triethylsilyl ether 
• 17942-89-1 triethyl-(3-phenyl-propenyloxy)-silane 
• 18531-94-7 (R)-1,1'-Bi-2-naphthol 

Relevant articles and documents

Novel antimycin derivative containing 3-hydroxybenzoic acid group and preparation method and application thereof

The invention relates to the technical field of medicinal chemistry, in particular to a novel-structure novel antimycin derivative containing 3-hydroxybenzoic acid group, produced by fermentation of streptomyces S.conglobates ATCC 31005, and a preparation method and application thereof in preparation of antitumor drugs. The molecular structure of the novel antimycin generally contains a 3-N-formylaminosalicylic acid group, while the molecular structure of the UAT-B-E provided by the invention is correspondingly provided with a 3-hydroxybenzoic acid group. An anti-tumor cell test finds that theinhibitory activity of UAT-B-E on human lung cancer cells, colorectal cancer cells and melanoma cells is equivalent to that of a control drug Cisplatin, and the toxicity to non-cancer cell lines is weak, so that UAT-B-E is expected to be developed into a tumor inhibitor.

Facially controlled C-methylation of oxolanyl and cyclopentyl acetate enolates: Application to the total synthesis of (+)-nephromopsinic acid

The stereoselectivity of the C-methylation of oxolanyl and cyclopentyl acetate enolates 5a-22a was investigated. The configuration of the C-methyl diastereomers was elucidated by a combination of crystal structure analysis, NMR spectroscopy and chemical correlations. Generally, the methylation proceeded re*-selectively, although with very different degrees of selectivity. The most important stereodirecting effect was a steric one exerted by the 5-phenethyl substituent, and this steric effect was strongly increased by the stereodirecting effect of a 3-OR group. Contrary to previous literature evidence, the endocyclic oxolanyl oxygen does not exert an effect. These findings were applied in a highly stereoselective synthesis of (+)-nephromopsinic acid (94). Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005.